Optimeos
Optimeos develops next-generation nanoparticle drug delivery technology enabling the use of biologics, peptides, and RNA to treat diseases beyond the capabilities of viral and lipid nanoparticle (LNP) delivery. The platform offers two formulation types: CINCs (Coated Inverse NanoCarriers) for targeted intracellular delivery of mRNA, DNA, and other therapeutic cargo, and LINCs (Long-acting Inverse NanoCarriers) for…
Funding snapshot
About
Optimeos develops next-generation nanoparticle drug delivery technology enabling the use of biologics, peptides, and RNA to treat diseases beyond the capabilities of viral and lipid nanoparticle (LNP) delivery. The platform offers two formulation types: CINCs (Coated Inverse NanoCarriers) for targeted intracellular delivery of mRNA, DNA, and other therapeutic cargo, and LINCs (Long-acting Inverse NanoCarriers) for sustained extracellular delivery of peptides over weeks to months. Key differentiators include unmatched multi-payload co-encapsulation capability for combining mRNA, siRNA, DNA, proteins, and peptides; enhanced tissue targeting with modular assembly to avoid liver clearance; superior dosing profiles with higher cargo content and precise release control; and tunable immunogenicity for repeat dosing or adjuvant-enhanced immunity. The pipeline includes hepatic gene replacement for Citrullinemia Type 1, in vivo T cell engineering for autoimmune and cancer indications, and a long-acting GLP-1 depot providing zero-order pharmacokinetics over 30-60 days. Founded in 2016 and headquartered in Princeton, United States, the company has raised approximately $4.2M in Series A funding from investors including America's Seed Fund, National Science Foundation, and Hatch BioFund.
Business model
Nanotechnology > Nanoenabled Products > Life Science > Drug Delivery > Vaccine,
Drug Delivery > Nanoparticle Based > Nanocarriers
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.